John Reed, Sanofi’s global head of R&D (Image: Endpoints News)

IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

Sanofi and Re­gen­eron have hus­tled up a sec­ond piv­otal tri­al for their IL-6 drug Kevzara as a po­ten­tial ther­a­py for se­vere cas­es of Covid-19. The part­ners swift­ly as­sem­bled a study draw­ing pa­tients from Italy, Spain, Ger­many, France, Cana­da and Rus­sia, plan­ning to sign up 300 pa­tients in a Phase II to test a low and high dose of Kevzara against place­bo, set­ting the stage for the Phase III fol­lowup.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.